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In the continuum of patients with Alzheimer’s disease (AD), mild cognitive impairment (MCI), and normal controls, a possible
association of verbal memory and endogenous estradiol (E2) levels was investigated. Verbal episodic memory was measured with
a german version of the California verbal memory test (CVLT). Results were controlled for apolipoprotein E (ApoE) phenotype.
We studied 37 controls, 32 MCIs and 117 ADs. Groups diﬀered in all trials of the CVLT (P<0.001) and in E2 levels (P<0.001).
E2 levels diﬀered signiﬁcantly between groups only among females (P<0.001). In females correcting for age and ApoE, there was
an overall correlation between CVLT delayed recall and level of E2 (P = 0.025). Stepwise regression analyses found E2 level to be a
signiﬁcant predictor for CVLT delayed recall (P<0.001). It may be concluded that lower E2 levels occur more in the course of the
disease than may be considered as a risk factor per se.
1.Introduction
Alzheimer’s dementia is the most frequent dementia. Clin-
ically, well-established criteria have proven their overall
accuracy and usefulness [1]. Besides a characteristic neu-
ropsychological course of the disease [2], several biolog-
ical markers have been proposed including characteristic
patterns of blood ﬂow and glucose utilization [3–6], an
increase of tau protein levels in cerebrospinal ﬂuid, and
a decrease of amyloid beta (1–42) protein [7, 8]. Also, in
patients with Alzheimer disease, an increase of endogenous
glucocorticoids was found [9]. Increased cortisol levels
aﬀect hippocampal neuron survival and potentiate beta-
amyloid toxicity. Similarly, under experimental conditions,
neuroprotection was found upon exogenous application of
estradiol [10], most likely through a reductive eﬀect of the
amyloid-beta-induced toxicity [11].
Estradiol experimental studies have shown that estradi-
ol may be neuroprotective in Alzheimer’s disease (AD) and
reduces amyloid toxicity [12]. Epidemiological evidence
suggested that hormone replacement therapy might be
beneﬁcial in aged women [13, 14] but the results are
still under dispute [15]. However, in a more recent large
placebo-controlled, double-blind study including 4532 post-
menopausal women not only no positive eﬀe c to fac o m b i -
nation of estrogen and progestin [16] or estrogen alone on
cognition but even a higher incidence of, AD was observed.
Contrary in another but only small placebo-controlled,
double-blind trial in manifest AD women estradiol demon-
strated a signiﬁcant eﬀect on verbal and visual memory and
attention compared with placebo [17]. Even less is known
about endogenous estrogen levels in aging and dementia.
In a recent study, lower E2 levels were correlated with
poor cognition, behavioral and functional status in older
individuals and AD patients [18]. A controversially result
was reported by Cunningham et al. [19] in a cross-sectional
study where neither a diﬀerence in estradiol levels between
AD women and controls nor a correlation to cognitive tests
was observed. However, estradiol may decline in women that
develop AD [20].
With higher age, estradiol levels decrease in females and
males [21, 22]. It was thus a goal of the current study2 Current Gerontology and Geriatrics Research
to investigate whether endogenous estradiol in Alzheimer’s
disease is similar to aged controls and mild cognitive
impairment as deﬁned by Petersen et al. [23] and whether
there is an association to verbal memory, the hallmark of
AD’s neuropsychological deﬁcit.
2.MaterialandMethods
2.1. Subjects and Patients. Subjects were recruited from the
Memory Clinic, Department of Neurology, University of
Ulm. Of 190 consecutive subjects, 4 were excluded because
of current estrogen replacement therapy. The remaining
186 were aged 35 to 89 years, 83 were men (age 35 to
88 years, median ± SD: 66.9 ± 10.27y), and 103 were
w o m e n( a g e4 4t o8 9y e a r s ,m e d i a n± SD: 70.2 ± 9.6y).
Medical histories were obtained and physical examinations
performed. Alzheimer’s disease was diagnosed using the
NINCDS-ADRDA [1]. Mild cognitive impairment (MCI)
wasdiagnosedaccordingtothecriteriabyPetersenetal.[23].
32 were classiﬁed as MCI (age 65.5 ± 6.9y, 9 females and 23
males,MMST28.1 ± 1.7) and 117 as AD (age72.0 ± 8.3y, 77
females and 40 males, MMST 21.9 ± 5.6), while there were
37 controls (age 60.7 ± 11.3 y, MD ± SD, 17 females and
20 males, MMST 29.2 ± 1.2). Controls were recruited from
the memory clinic as well, admitted for subjective memory
complaints or because of a positive family history where a
cognitive impairment could be ruled out.
2.2. Neuropsychological Testing. The Mini-Mental State Ex-
amination [24] was used to assess cognitive functioning. In
the verbal episodic memory task (California verbal memory
test (CVLT)), ﬁve consecutive trials of the same list have to
be remembered followed by a short (CVLT SD) and a long
delayed recall (CVLT LD) as well as a recognition condition
(CVLT rec) [25].
2.3. Clinical Chemistry. Blood samples were collected via
venipuncture. Analysis of samples was conducted within 1
month of blood being drawn. Levels of E2 were measured
by radioimmunoassay (double antibody technique) using a
commercial kit.
2.4. Statistics. Statistical analysis was performed using a soft-
ware program (SPSS 11.0; SPSS Inc, Chicago, Ill). Analysis
of variance was used to test for heterogeneity with Tukey-B
posthocanalysisforsigniﬁcantgroupdiﬀerencesfollowedby
an ANCOVA where variables signiﬁcantly diﬀerent between
groups were included. Spearman correlation coeﬃcients
were used where applicable to assess an association among
measures. A stepwise regression was applied to assess the
main contributing factors for verbal memory functioning.
3. Results
190 subjects were investigated, and 4 were excluded because
of current estrogen replacement therapy. The remaining 37
control subjects, 32 MCIs and 117 patients with Alzheimer’s

































Figure 1: Diﬀerences of estradiol levels in controls, MCI, and AD
patients (gender considered separately).
(ApoE) ε4 carriers, age, and general intelligence (Table 1),
thus, in further analyses, data were controlled for age, ApoE
ε4, and gender.
To assess for group diﬀerences of E2 levels, analyses of
variance (ANOVA) were applied that revealed a signiﬁcant,
diﬀerence (F(2, 183) = 12.6, P<0.001) indicating an
impaired cognitive status to be associated with a decreased
E2. Tukey post hoc analyses revealed only signiﬁcant diﬀer-
ences between the controls and AD (mean diﬀerence: 18.3
± 3.8 Pg/mL, P<0.001, 95%-CI: 9.5–27.3 Pg/mL), but
not MCI (P = 0.117). Between AD and MCI diﬀerence
was almost signiﬁcant (mean diﬀerence: 8.8 ± 4.0 Pg/mL,
P = 0.07, 95%-CI: 18.2–0.6 Pg/mL). Additionally, group
diﬀerences in the CVLT were observed (Table 1).
When the group comparison was stratiﬁed for gender,
there were no diﬀerences of E2 for men (F(2, 80) =.2, P>
0.05) but for women (F(2, 99) = 20.9, P<0.001). In Tukey
posthoc,AD(meandiﬀerence:36.2 ±5.6 Pg/mL,P<0.001,
95%-CI: 49.6–22.8 Pg/mL) and MCI (mean diﬀerence: 23.9
± 8.7 Pg/mL, P = 0.019, 95%-CI: 44.5–3.2 Pg/mL) had
lower E2 level than controls. There were no diﬀerences in the
E2 level between MCI and AD (Figure 1).
To ﬁnd out if lower E2 is independently associated to
AD and MCI diagnosis in further analyses, an ANCOVA
comparison of E2 between groups adjusted for signiﬁcant
noncognitive variables was performed. After including age,
gender, and ApoE status, the model remained signiﬁcant
(F(7, 162) = 8.2, P<0.001) with group (P<0.001) and
age (P<0.001) as signiﬁcant independent variables. Also,
the interaction group x age was signiﬁcant (P<0.001).Current Gerontology and Geriatrics Research 3
Table 1: Demographic and clinical data of study subjects.
Controls (n = 37) MCI (n = 32) AD (n = 117) P value
Age (years) 60.7 ± 11.3‡ 65.5 ± 6.9 72.0 ± 8.6‡ < 0.001
MMSE∗ 29.2 ± 1.2‡ 28.1 ± 1.7 21.9 ± 8.6‡ < 0.001
Gender female/male 17/20 9/23§ 77/40§ < 0.001
E2 (pg/mL) 39.4 ± 31.3‡, 29.8 ± 20.5 21.0 ± 14.5‡ < 0.001
0A P O Eε4-isoallels 84.4%‡ 75.0%§ 38.7%‡,§ < 0.001
1 15.6% 18.8% 48.6%
2 0% 6.3% 12.6%
CVLT SD 14.0 ± 2.5‡,¶ 9.2 ± 3.8§,¶ 5.2 ± 2.8‡,§ < 0.001
CVLT LD 13.9 ± 2.6‡,¶ 9.2 ± 3.9§,¶ 4.5 ± 2.9‡,§ < 0.001
CVLT Rec 15.8 ± 0.5‡,¶ 14.2 ± 1.8§,¶ 12.4 ± 3.2‡,§ < 0.001
∗Mini-Mental Status Exam.
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Figure 2: Association of estradiol level and CVLT delayed recall for
all female subjects.
Spearman correlation showed a relation between estro-
gen and MMSE (r = 0.273, P<0.001), CVLT short delay
(SD) (r = 0.197, P = 0.036), and CVLT delayed recall
(LD) (r = 0.208, P = 0.026). There was no association of
CVLT recognition and estrogen (r = .121, P = 0.2). When
analyses was stratiﬁed for gender, there was no association
of E2 with MMSE (r = .06, P>0.05), CVLT SD (r =
−.05, P>0.05), CVLT LD (r =− .05, P>0.05), and CVLT
rec (r = .06, P>0.05) in men. In women, a lower E2 was
associated with a worse MMSE (r = .249, P = 0.017), CVLT
SD (r = .417, P = 0.004), and CVLT LD (r = .428, P =
0.003; Figure 2). There was a tendency for a lower E2 to be
associated with an impaired CVLT rec (r = .28, P = 0.06).
In univariate analysis with CVLT scores and MMSE as
dependent variables, MMSE (F(1, 171) = 14.6, P<0.001),
CVLT SD (F(1, 171) = 9.4, P = 0.003), CVLT LD (F(1,
171) = 11.7, P = 0.001), and CVLT rec (F(1, 171) = 4.8,
P = 0.03) were signiﬁcantly associated with E2. In a linear
stepwise regression analyses, correcting for age, gender and,
ApoE E2 turned out to be a signiﬁcant predictor of CVLT
SD (F(1, 171) = 9.8, r = 0.408, P<0.001) and CVLT LD
(F(1, 171) = 9.7, r = 0.407, P<0.001). Stratiﬁed for gender,
there was no association in men for MMSE (P>0.05),
CVLT SD (P>0.05), CVLT LD (P>0.05), and CLT rec
(P>0.05). In women, regression analysis revealed CVLT
LD only to be a signiﬁcant predictor of E2 level (F(1, 79) =
17.9, P<0.001), while there was no signiﬁcant association




and memory functioning. This preliminary study showed
that in, AD, as well as in MCI, E2 levels were reduced
compared to healthy controls. Moreover, this ﬁnding was
accompanied with a correlation of E2 and verbal episodic
memory delayed recall. So far, our results support formerly
published results [18] where in a group of dementia and
controls an association between E2 and a thai version of
the MMSE was reported. However, our results diﬀered from
those of Senanarong et al. [18] since they found their results
to be valid in men and women while our data could ﬁnd an
associationinwomenonly.Thismightbeduetotheirsmaller
sample size of AD patients. On the other hand, we were able
to, detect group diﬀerences in E2 level: in Alzheimer’s disease
and MCI, estrogen level was signiﬁcantly reduced compared
with controls, a ﬁnding that conﬁrms a lower E2 level in AD
comparedtohealthycontrols[26].Inanothercross-sectional
study, a higher E2 level was associated with a smaller risk to
have cognitive impairment [27].
For postmenopausal estrogen users, a lower estimated
risk to develop Alzheimer’s disease could be found in
previous epidemiologic studies [13, 14, 28–32]. However,4 Current Gerontology and Geriatrics Research
in a large and well-controlled study, the WHIMS, the
combination of estrogen and progesteron failed to prove a
beneﬁcial eﬀect, indeed mortality even rose under hormone
substitution [16]. More recently, it was shown that E2
replacement may be beneﬁcial in ApoE ε4 carriers although
it did not signiﬁcantly prevent from dementia for the whole
sample [33].
Limitation of our data is the confounding eﬀect of the
diﬀerent age distribution of the three groups although
there were no age diﬀerences between controls and MCI
as our major point of interest. Furthermore, particularly
the association of episodic memory and estrogen level was
stable to age eﬀects. Episodic memory is regarded as the
very early neuropsychological impairment in AD and is
considered as the decisive hall-mark in MCI. In previous
studies, verbal memory seemed to be the most sensitive
cognitive domain to estrogen replacement therapy [17, 34],
respectively, the most preserved domain after hysterectomy
and eventual E2 treatment compared to placebo [35]. In
a large review, it was stated from randomized controlled
trials that ERT preferentially prevents verbal memory decline
in postmenopausal women [36]. Treatment eﬀects in older
healthy women are possibly only present in subjects with
preserved delayed verbal recall [31]. In summary our
ﬁndings of a decreased estrogen level in the course of AD
as early as in the stage of MCI as well as the ﬁndings
in the literature of a preponderant positive eﬀect of ERT
on verbal memory provide evidence that a reduction of
the estrogen level contributes to AD pathogenesis. From
neurophysiological studies, several possible biological eﬀects
have been described, among others a diminished amyloid-
beta toxicity [11, 12], promotion of cholinergic activity
in the brain [37], stimulation of axonal spouting and
dendritic spine formation [38, 39], and slowing of cerebral
atherosclerosis [40].
The advantage of this study was a comparison of E2 levels
inhealthycontrolsandagroupwithADunderconsideration
of MCI patients that are thought to be a group at risk to
develop AD. Therefor, early changes that might be relevant
for or precede AD might be detectable in MCI. Although
there is quite a body of evidence that estrogen is reduced
in AD, so far there is a lack of studies in MCI. This is the
ﬁrst study to provide data on E2 levels in MCI. Results of
our study suggest that E2 level is indeed decreased in MCI
compared to controls. This reduction may reﬂect a higher
vulnerability to develop AD. Very recently, in men with MCI,
a tentative positive eﬀect of hormone replacement therapy
could be observed [41].
Finally,alimitationofourstudyhastobementionedthat
it is cross-sectional in design that weakens the conclusions to
be drawn from the results.
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